U.S. Life Science Tools Market Size & Trend Report, 2024-2033
The U.S. life science tools market size reached USD 57.19 billion in 2023 and is projected to hit around USD 140.44 billion by 2033, expanding at a CAGR of 9.4% during the forecast period from 2024 to 2033.
Key Takeaways:
U.S. Life Science Tools Market Growth
This can be attributed to a rise in government funding for life science technologies, growth of cell & gene therapies, increase in demand for biopharmaceuticals, and rise in competition among prominent market entities. An increase in the number of strategic deals & developments, coupled with growing investments in R&D for life science tools, is expected to further drive the market. The increase in revenue is primarily attributed to the swift progress made by life science tool companies in areas such as sequencing, mass spectrometry, chromatography, nuclear magnetic resonance, and other diverse products.
The U.S. accounted for over 44.8% of the global life science tools market in 2023. The market is propelled by investments and funding aimed at developing advanced therapeutics, coupled with a persistent demand for innovative medicines and treatments. This demand is fuelled by the escalating prevalence of diseases like cancer, kidney and thyroid disorders, and diabetes. The COVID-19 pandemic has had a significant effect on numerous industries and their related supply chains worldwide. This is primarily due to interruptions in the provision of essential materials, such as a lack of raw materials and workforce. Moreover, the transportation of raw materials across various regions was suspended. These circumstances have resulted in a deficit of medical supplies, including molecular and immunoassay kits, digital solutions, life-support machines, and medications in various parts of the world.
Moreover, the pandemic has led the market to develop quick diagnostic tests for the SARS-CoV-2 virus, leading manufacturers to introduce innovative solutions. Some of these tests identify the SARS-CoV-2 nucleic material using the PCR technique or methods related to nucleic acid hybridization, while others are serological and immunological assays that detect antibodies produced in response to the virus. For instance, in December 2021, Siemens Healthineers obtained Emergency Use Authorization from the U.S. FDA for its COVID-19 rapid test, CLINITEST Rapid COVID-19 Antigen Self-Test, which can be used for self-testing by individuals aged 14 and above. The market will be propelled by new developments related to the pandemic, government funding, product approvals, and ongoing product launches.
The market is expected to grow due to the increasing demand and development of gene and cell therapies. Companies are intensifying their research and development efforts to create effective gene therapies that address diseases at the genomic level, in response to the need for strong disease treatment methods. The number of products approved by the FDA is increasing, indicating a promising future for gene therapies. Furthermore, the progress in recombinant DNA technology is likely to increase the number of clinical trials for gene therapy. For example, the FDA anticipated receiving over 200 applications each year for clinical trials of cell and gene therapies by 2029, as of 2020.
The field of cancer therapy is witnessing rapid advancements with the evolution of monoclonal antibodies. As per a January 2021 article by mAbxience, 27 such antibodies have received approval for the treatment of various cancers. The use of biologics is expanding due to the increasing FDA approvals of monoclonal antibodies in diagnostics and cancer therapy. For example, in January 2022, the FDA approved a monoclonal antibody named Tebentafusp-tebn, which is beneficial in treating metastatic uveal melanoma. The market growth is expected to be propelled by government support and the escalating demand for innovative therapeutics.
U.S. Life Science Tools Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 62.57 Billion |
| Market Size by 2033 | USD 140.44 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 9.4% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, product, end-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Agilent Technologies, Inc.; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; Bio-Rad Laboratories, Inc.; Danaher Corporation; Illumina, Inc.; Thermo Fisher Scientific, Inc.; QIAGEN N.V.; Merck KGaA; Shimadzu Corporation; Hitachi, Ltd.; Bruker Corporation; Oxford Instruments plc; Zeiss International |
Segments Insights:
Technology Insights
Cell biology technology dominated the market and accounted for the largest share of 33.11% in 2023. Continuous developments in cells analysis technologies such as microscopy, cytometry, high content analysis, have a significant impact over the growth of immunology, oncology research, stem cell research, and drug discovery. For instance, a novel nanofluidic technology developed with early input by Amgen and invented by Berkeley Lights uses light to manipulate cells. This novel digital cell biology technology can enable scientists’ resource-efficient and rapid ways to run standard biotech experiments. Introduction of novel technologies for usage and adoption of stem cells, CAR T-cells, TCR T-cells, NK T-cells, and other cell therapies boosts revenue generation in this segment. Automation in the storage and processing of cord blood and adult stem cells is expected to positively influence segment growth.
Genomics technology is expected to grow at the fastest CAGR of 12.7% over the forecast period. Genomics, which encompasses the evolutionary, comparative, and functional study of genomes, has seen a rapid expansion in its product range for conducting genomic analysis, thanks to the advent of various supportive technologies. Major innovators such as Thermo Fisher Scientific, QIAGEN, Illumina, and Pacific Biosciences of California, Inc. are at the forefront of developing instruments for diverse genomic applications. The increasing awareness of genomics’ role in managing human diseases and its potential in unconventional applications has spurred the use of genomic data. This has intensified competition among companies to launch new products and technologies that utilize genetic information, thereby tapping into the abundant opportunities in the market.
Product Insights
Cell culture systems and 3D cell culture dominated the market and held the largest share of 18.9% in 2023. Research into the potential of cell biology have yielded significant breakthroughs, thereby contributing to revenue growth. Comprehensive understanding of cell biology has become a crucial component in laboratory workflows, paving the way for market expansion. Furthermore, life science researchers are keen to incorporate new and sophisticated instruments, which is anticipated to strengthen this segment further. This trend in the industry has also motivated numerous major manufacturers to broaden their range of instruments. Companies such as Cytiva, BioTek Instruments, Horizon Discovery, and Seahorse Bioscience, to name a few, are striving to launch instruments related to cell analysis, cell biology, and imaging.
Next-generation sequencing (NGS) is expected to grow at the fastest CAGR of 19.8% during the forecast period. NGS systems enable the concurrent sequencing of numerous genome samples. These systems are adept at handling a vast array of sequencing reactions at the same time. The streamlining of the NGS process, coupled with ongoing reductions in the cost of equipment and reagents, is expected to encourage more widespread use of this biotechnological method. Furthermore, advancements in bioinformatics are likely to increase the use of NGS in both high-throughput and even low-throughput research. For instance, in February 2022. Beckman Coulter Life Sciences entered into an application development agreement with Illumina, Inc. for the Biomek NGeniuS Next Generation Library Preparation System.
End-use Insights
The healthcare segment dominated the market and held the largest share of over 32.8% in 2023 and is expected to grow at the fastest CAGR during the forecast period. The increasing use of proteomic and genomic workflows in hospitals for diagnosing and treating various diseases is anticipated to spur growth. Furthermore, the rising use of tissue diagnostics and NGS services in hospitals is predicted to propel the market. Numerous hospitals and clinics are presently offering sequencing facilities to patients and are exploring the application of advanced tools and technology in everyday medical practice. Stanford Medicine, for instance, offers sequencing services to individuals with rare or undiagnosed genetic conditions. Partners HealthCare in the U.S. is among the first hospital systems to provide public genomic sequencing, analysis, and interpretation services. The use of genomic sequencing in a hospital or clinical environment is expected to enhance patient care while reducing healthcare costs. As a result, the healthcare sector is projected to experience the most rapid growth in the coming years.
Biopharmaceutical companies is expected to have a lucrative growth during the forecast period. The surge in biopharmaceutical R&D activities is fostering the use of life science tools. Companies like Thermo Fisher Scientific and Merck KGaA have invested heavily in bioprocessing capabilities and biopharmaceutical manufacturing units, respectively. The growing demand for biologics has led to increased investments in expanding manufacturing facilities. For example, Alexion invested in drug production facilities in Ireland, and Upperton Pharma Solutions invested in facility expansion, significantly increasing R&D space and GMP manufacturing. These strategic initiatives, aimed at enhancing the production of novel biologics, are expected to drive market growth.
U.S. Life Science Tools Market Recent Developments
Key U.S. Life Science Tools U.S. Life Science Tools Market Company Insights
The U.S. life science tools market is intensely competitive, with numerous players offering innovative products. These companies are constantly broadening their product portfolios and introducing new platforms through rigorous R&D to maintain their market position. In addition, strategic actions by leading firms, such as collaborations, mergers, acquisitions, and product launches, are driving market growth and heightening competition. For example, Agilent Technologies, Inc. formed a partnership with Biosciences, Inc. in February 2022 to integrate the AVITI System with SureSelect target enrichment panels, enhancing customer access to genomic tools. This initiative is anticipated to open new growth avenues for the company.
Key U.S. Life Science Tools Companies:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Life Science Tools market.
By Technology
By Product
By End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Product
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in U.S.
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Life Science Tools Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increased government funding for life science technologies
3.2.1.2. Growth of cell and gene therapies
3.2.1.3. Rise in the demand for biopharmaceuticals (biologics & biosimilars)
3.2.1.4. Technological advancements in life science tools
3.2.1.5. Applications of genomic and proteomic technologies for precision medicine
3.2.2. Market restraint analysis
3.2.2.1. High cost for some technologies
3.2.2.2. Dearth of skilled professionals
3.3. U.S. Life Science Tools Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTEL Analysis
Chapter 4. U.S. Life Science Tools Market: Technology Estimates & Trend Analysis
4.1. U.S. Life Science Tools Market: Technology Dashboard
4.2. U.S. Life Science Tools Market: Technology Movement Analysis
4.3. U.S. Life Science Tools Market Size & Forecasts and Trend Analyses, 2020 to 2033 for the following
4.4. Genomic Technology
4.4.1. Market estimates and forecasts 2020 to 2033
4.5. Proteomics Technology
4.5.1. Market estimates and forecasts 2020 to 2033
4.6. Cell Biology Technology
4.6.1. Market estimates and forecasts 2020 to 2033
4.7. Other Analytical & Sample Preparation Technology
4.7.1. Market estimates and forecasts 2020 to 2033
4.8. Lab Supplies & Technology
4.8.1. Market estimates and forecasts 2020 to 2033
Chapter 5. U.S. Life Science Tools Market: Product Estimates & Trend Analysis
5.1. U.S. Life Science Tools Market: Product Dashboard
5.2. U.S. Life Science Tools Market: Product Movement Analysis
5.3. U.S. Life Science Tools Market Size & Forecasts and Trend Analyses, 2020 to 2033 for the following
5.4. Cell Culture Systems & 3D Cell Culture
5.4.1. Market estimates and forecasts 2020 to 2033
5.4.2. Instruments
5.4.2.1. Market estimates and forecasts 2020 to 2033
5.4.3. Consumables
5.4.3.1. Market estimates and forecasts 2020 to 2033
5.4.4. Cell & Tissue Culture Services
5.4.4.1. Market estimates and forecasts 2020 to 2033
5.5. Liquid Chromatography
5.5.1. Market estimates and forecasts 2020 to 2033
5.5.2. Instruments
5.5.2.1. Market estimates and forecasts 2020 to 2033
5.5.3. Consumables
5.5.3.1. Market estimates and forecasts 2020 to 2033
5.5.4. Services
5.5.4.1. Market estimates and forecasts 2020 to 2033
5.6. Mass Spectrometry
5.6.1. Market estimates and forecasts 2020 to 2033
5.6.2. Instruments
5.6.2.1. Market estimates and forecasts 2020 to 2033
5.6.3. Consumables
5.6.3.1. Market estimates and forecasts 2020 to 2033
5.6.4. Services
5.6.4.1. Market estimates and forecasts 2020 to 2033
5.7. Flow Cytometry
5.7.1. Market estimates and forecasts 2020 to 2033
5.7.2. Instruments
5.7.2.1. Market estimates and forecasts 2020 to 2033
5.7.3. Consumables
5.7.3.1. Market estimates and forecasts 2020 to 2033
5.7.4. Services
5.7.4.1. Market estimates and forecasts 2020 to 2033
5.8. Cloning & Genome Engineering
5.8.1. Market estimates and forecasts 2020 to 2033
5.8.2. Kits, Reagents, and Consumables
5.8.2.1. Market estimates and forecasts 2020 to 2033
5.8.3. Services
5.8.3.1. Market estimates and forecasts 2020 to 2033
5.9. Microscopy & Electron Microscopy
5.9.1. Market estimates and forecasts 2020 to 2033
5.9.2. Instruments
5.9.2.1. Market estimates and forecasts 2020 to 2033
5.9.3. Consumables
5.9.3.1. Market estimates and forecasts 2020 to 2033
5.9.4. Services
5.9.4.1. Market estimates and forecasts 2020 to 2033
5.10. Next Generation Sequencing
5.10.1. Market estimates and forecasts 2020 to 2033
5.10.2. Instruments
5.10.2.1. Market estimates and forecasts 2020 to 2033
5.10.3. Consumables
5.10.3.1. Market estimates and forecasts 2020 to 2033
5.10.4. Services
5.10.4.1. Market estimates and forecasts 2020 to 2033
5.11. PCR & qPCR
5.11.1. Market estimates and forecasts 2020 to 2033
5.11.2. Instruments
5.11.2.1. Market estimates and forecasts 2020 to 2033
5.11.3. Consumables
5.11.3.1. Market estimates and forecasts 2020 to 2033
5.11.4. Services
5.11.4.1. Market estimates and forecasts 2020 to 2033
5.12. Nucleic Acid Preparation
5.12.1. Market estimates and forecasts 2020 to 2033
5.12.2. Instruments
5.12.2.1. Market estimates and forecasts 2020 to 2033
5.12.3. Consumables
5.12.3.1. Market estimates and forecasts 2020 to 2033
5.12.4. Services
5.12.4.1. Market estimates and forecasts 2020 to 2033
5.13. Nucleic Acid Microarray
5.13.1. Market estimates and forecasts 2020 to 2033
5.13.2. Instruments
5.13.2.1. Market estimates and forecasts 2020 to 2033
5.13.3. Consumables
5.13.3.1. Market estimates and forecasts 2020 to 2033
5.13.4. Services
5.13.4.1. Market estimates and forecasts 2020 to 2033
5.14. Sanger Sequencing
5.14.1. Market estimates and forecasts 2020 to 2033
5.14.2. Instruments
5.14.2.1. Market estimates and forecasts 2020 to 2033
5.14.3. Consumables
5.14.3.1. Market estimates and forecasts 2020 to 2033
5.14.4. Services
5.14.4.1. Market estimates and forecasts 2020 to 2033
5.15. Transfection Devices & Gene Delivery Technologies
5.15.1. Market estimates and forecasts 2020 to 2033
5.15.2. Equipments
5.15.2.1. Market estimates and forecasts 2020 to 2033
5.15.3. Reagents
5.15.3.1. Market estimates and forecasts 2020 to 2033
5.16. NMR
5.16.1. Market estimates and forecasts 2020 to 2033
5.16.2. Instruments
5.16.2.1. Market estimates and forecasts 2020 to 2033
5.16.3. Consumables
5.16.3.1. Market estimates and forecasts 2020 to 2033
5.16.4. Services
5.16.4.1. Market estimates and forecasts 2020 to 2033
5.17. Other Separation Technologies
5.17.1. Market estimates and forecasts 2020 to 2033
5.17.2. Instruments
5.17.2.1. Market estimates and forecasts 2020 to 2033
5.17.3. Consumables
5.17.3.1. Market estimates and forecasts 2020 to 2033
5.17.4. Services
5.17.4.1. Market estimates and forecasts 2020 to 2033
5.18. Other Products & Services
5.18.1. Market estimates and forecasts 2020 to 2033
5.18.2. Antibodies
5.18.2.1. Market estimates and forecasts 2020 to 2033
5.18.3. General Supplies
5.18.3.1. Market estimates and forecasts 2020 to 2033
5.18.4. Others
5.18.4.1. Market estimates and forecasts 2020 to 2033
5.18.4.2. Instruments
5.18.4.2.1. Market estimates and forecasts 2020 to 2033
5.18.4.3. Consumables
5.18.4.3.1. Market estimates and forecasts 2020 to 2033
5.18.4.4. Services
5.18.4.4.1. Market estimates and forecasts 2020 to 2033
Chapter 6. U.S. Life Science Tools Market: End-use Estimates & Trend Analysis
6.1. U.S. Life Science Tools Market: End-use Dashboard
6.2. U.S. Life Science Tools Market: End-use Movement Analysis
6.3. U.S. Life Science Tools Market Size & Forecasts and Trend Analyses, 2020 to 2033 for the following
6.4. Government & Academic
6.4.1. Market estimates and forecasts 2020 to 2033
6.5. Biopharmaceutical Company
6.5.1. Market estimates and forecasts 2020 to 2033
6.6. Healthcare
6.6.1. Market estimates and forecasts 2020 to 2033
6.7. Industrial Applications
6.7.1. Market estimates and forecasts 2020 to 2033
6.8. Others
6.8.1. Market estimates and forecasts 2020 to 2033
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company market share/position analysis, 2023
7.3.2. Agilent Technologies, Inc.
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Becton, Dickinson and Company
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. F. Hoffmann-La Roche Ltd.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Bio-Rad Laboratories, Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Danaher Corporation
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Illumina, Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Thermo Fisher Scientific, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. QIAGEN N.V.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Merck KGaA
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Shimadzu Corporation
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Hitachi, Ltd.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Bruker Corporation
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Oxford Instruments plc
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Zeiss International
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers